Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -4.00 -8.0% 46.00 5,322,935 16:35:04
Bid Price Offer Price High Price Low Price Open Price
46.00 47.00 50.50 45.50 50.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -4.79 -3.55 55
Last Trade Time Trade Type Trade Size Trade Price Currency
17:07:19 O 30,000 47.30 GBX

Synairgen (SNG) Latest News

More Synairgen News
Synairgen Takeover Rumours

Synairgen (SNG) Discussions and Chat

Synairgen (SNG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Synairgen trades in real-time

Synairgen (SNG) Top Chat Posts

Synairgen Daily Update: Synairgen Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 50p.
Synairgen Plc has a 4 week average price of 45.50p and a 12 week average price of 18.25p.
The 1 year high share price is 77p while the 1 year low share price is currently 5.75p.
There are currently 120,376,737 shares in issue and the average daily traded volume is 2,016,857 shares. The market capitalisation of Synairgen Plc is £55,373,299.02.
lauders: Polaris Capital joined as a shareholder during the last fundraiser to the best of my knowledge. In April they mentioned SNG here: Https:// Q: And what about the second set of drugs in clinical trials? GP: These are anti-inflammatory agents. In patients who unfortunately experience a more serious infection, the immune system can, in simple terms, go out of control in what is described as a cytokine storm. This can lead to serious lung damage and a poor outlook for the patient. Actemra and Kevzara are currently used to treat rheumatoid arthritis which is an autoimmune disease.They target a cytokine called Interleukin 6 (IL6) which is released as part of this cytokine storm. These drugs have been used in patients with positive reports and the companies are running trials as we speak to see if these two drugs are effective. Synairgen, a UK-based biotech company, is starting a trial using their development candidate which is inhaled Interferon Beta, designed to regulate antiviral defences in the lungs particularly in patients considered the most at risk from COVID-19. Data from these studies with these drugs are due in the next two to three months. I also don't recall seeing this but it was no doubt shared at some point: Http:// My view Of course, we’ve this problem that no one at all currently knows whether the drug is going to work like people think it might. We face uncertainty here, not just risk. And yet, we have a drug that is at least good enough to trial on humans. For the disease du jour, meaning that if it is effective at all, it will have near no problems with licencing and won’t have to spend much on marketing. The company is also though that process of testing. It’s highly likely that the company will also benefit from streamlined approval – assuming any of that effectiveness. So, yes, it’s a high risk that the clinical effectiveness exists at all. But all of the other usual problems have been swept away. The downside here is that it’s a bust in that it doesn’t treat the infection. The upside is that it might – and also that near all of the other barriers to completion have been swept away. The company is financed, and the regulatory apparatus is primed to be helpful to it. The investor view This is obviously significantly speculative, and none of us can possibly know how it’s going to perform in those trials. Yet, given all of the other issues, it’s worth a speculative punt. A small amount from the tail end of the portfolio, certainly nothing more than a percent or so of total holdings. I concur with the Sunday Times – Synairgen stock is a Buy in modest quantities given the risks. The share price at the time of the above on 2nd April was around the levels we are at now. Since then the share price has spiked above 70p twice! Third time lucky? Will it ever hold above 70p? Answers to come over the next few weeks!
lauders: This may have been shared before (so apologies if so) but SNG and as it happens DDDD are mentioned here: Https:// This month, I take look at three of these companies, all of which are leading the fight against Covid-19 and look to have good growth prospects. As with all early-stage health care companies however, investors should be aware that they remain highly speculative and primarily focused on long-term outcomes. Relevant to this BB: Breath of fresh air Shares in Synairgen have risen more than tenfold so far in 2020, starting the year at just below 6p to currently trade at 60.5p. At that price investors are valuing the business at just over £90m. In terms of finances, Synairgen had cash of £2.54m as at 31 December last year. Then in March this year, £14m was raised at a price of 35p per share, with the equity placing, unsurprisingly, being heavily oversubscribed. The company will spend £7m of this on Covid-19 clinical trial activity, £4m on the manufacture of the SNG001 drug product and other supplies, with the remainder being set aside for working capital and other matters. Analysts at finnCap have a net present value-based target price of 120p on the shares, almost double the current share price. Around 80p per share of this value relates to the use of SNG001 in Covid-19 patients. However, should the Phase II study be successfully completed, the broker anticipates that its valuation rising to as much as 360p, providing significant ‘blue-sky’ upside. So you can buy at a price just under that quoted when the above was typed, and I did on Friday ;-)
sgn001: Volsung If the placing took place last week then maybe yes it could return to 40p but since the placing, a distressed seller has continued to sell millions of shares and the share price remains stagnant. Thats a fantastic result thus far. The selling has been done in order to protect the share price so with all due respect i can't see the share price go that low until after the trials(subject to poor results which we are not expecting).
makendon: Motley Fool post from yesterday hTTps:// The Synairgen (LSE: SNG) share price has almost ten-bagged since the beginning of 2020. The company has a potential Covid-19 treatment, known as SNG001, so no surprise there. What’s more, on 18 March the firm released details of its testing plans. It’s not a coronavirus vaccine, but it could possibly be the next best thing. SNG001 is a based on an existing intravenous antiviral treatment. And Synairgen’s new inhaler version will deliver the drug directly to the lungs, where the coronavirus does its damage. This stuff sounds like it could be a potential lifesaver. As it’s based on an existing well-tested treatment, the trial and approval process could potentially be a lot quicker than for any coronavirus vaccine or treatment being developed from scratch. Claim your FREE copy of The Motley Fool’s Bear Market Survival Guide. Global stock markets may be reeling from the coronavirus, but you don’t have to face this down market alone. Help yourself to a FREE copy of The Motley Fool’s Bear Market Survival Guide and discover the five steps you can take right now to try and bolster your portfolio… including how you can aim to turn today’s market uncertainty to your advantage. Click here to claim your FREE copy now! The testing started at the end of March. Synairgen CEO Richard Marsde said: “A successful outcome from this trial in Covid-19 patients would be a major breakthrough in the fight against this coronavirus pandemic.” Let’s hope that turns out to be an understatement. Coronavirus vaccine candidates In a report last month, examined 14 companies developing coronavirus vaccines and treatments. Many have seen their share prices soar, but the report points out that they won’t all succeed. The World Health Organization reckons there are more than 50 coronavirus vaccine candidates currently at various stages of development. We might see a small number of those making it through to production and big sales. But how can we decide which those will be? I can’t really see any other viable approach than guesswork. Most of the companies examined by are based in the US, unsurprisingly, and one of them sounds like it might have a potential advantage. Inovio Pharmaceuticals already has a vaccine for the MERS coronavirus, and I’d assume that would be a great help. Inovio is hoping to deliver a million doses by the end of the year. But its share price is up only a relatively modest 290% so far this year. Investors seem to be more excited by Synairgen. UK virus investment GlaxoSmithKline (LSE: GSK) is in the race too, providing its expertise in adjuvants to companies doing coronavirus vaccine research. I’d never heard of adjuvants before today, but they’re things that can be added to vaccines to boost their effectiveness. They sound like a sort of pharmacological catalyst to me. GlaxoSmithKline is surely not going to turn into a multibagger any time soon. Though if you’re looking for sure-fire short-term profits, I really can’t help you. But what I do like about GlaxoSmithKline’s involvement is that it makes it something of a ‘picks and shovels’ investment. You know, from the old gold rush days, when no matter who found the shiny stuff, those who sold the tools made nice profits. Quick growth punt? Should you take a punt on Synairgen, or any other coronavirus vaccine possibilities? As long as you understand the risk and you’re prepared for a loss if you get the wrong one, I don’t see a problem with investing a small amount of money. But I’d always recommend putting the bulk of your investment cash into long-term quality like GlaxoSmithKline. So in answer to my question in the headline: yes, you might get rich. But you might not. I’d rather go for steady returns compounded over time from a long-term holding in GSK.
lithological heterogeneities: MASSIVE POTENTIAL - £3.60+ TARGET 03 APR 20 This company has truely MASSIVE potential if the trial is,as hoped,positive. • For example, as noted by Finncap, when Gilead Sciences announced they were trialling Remdesivir for COVID-19, the share price went up so much that it added an EXTRA $11 BILLION to their market cap. • Finncap also noted that when Fujifilm Holdings,faviparivir (Avigan) began trials for COVID-19 is also added an EXTRA $3 BILLION to their market cap. • The current SNG market cap, at 50p, is just a paltry £60m in comparison. If SNG was listed in the USA, SNG would be trading at several pounds already. It is a huge disparity in valuation just because SNG are listed in the UK. Furthermore, Finncap suggested a valuation of £1.20 right now and £3.60 on a successful trial outcome. Now i know that you cant really believe broker targets,let alone the house broker targets who have a vested interest as Finncap obviously do, but remember two very important points that were NOT included in the above valuations: 1.....It does NOT include a Global Distribution deal with the likes of Astrzeneca or Merck. 2.....It does NOT include the $3 BILLION + that could be included in the valuation for stockpiling SNG001 as they allude to in their Note adding that the EU and US already stockplie in excess of $3 BILLION for Tamiflu. IN SHORT, SNG IS MASSIVELY UNDERVALUED RIGHT NOW LET ALONE ON A POSITIVE RESULT. FINNCAP NOTE (26 MAR 2020 + 31 MAR 20) Valuation. •To give a sense of the potential value of successful COVID-19 treatment (rather than vaccine), Gilead Sciences,(Remdesivir) stock price rose c.14% on the back of this news, adding c.$11bn to the value of Gilead. •Fujifilm Holdings,faviparivir (Avigan),share price rose c.15% on this news, implying an equity increase of c.£3bn. •We reiterate our rNPV-based target price of 120p, of which c.80p relates to the use of SNG001 in COVID-19 disease. The successful completion of the Phase II study (SG016) would imply a rNPV of as much as c.£475m or a c.360p target price – suggesting a c.£360m (240p) uplift on the current estimated NPV. •Not only would a positive trial help to address the current COVID-19 crisis but it could also offer governments the opportunity to stockpile a broad-spectrum antiviral product for future pandemics in the way that the US and European governments stockpiled significant levels of the antiviral, Tamiflu (>$3bn)."
borromini1: The SARS-CoV epidemic occurred between 2002 to 2003. In 2005 SNG had a share price of 150 GBX. MERS-CoV emerged in 2012. In 2012 to 2014 SNG had an share price of around 50 GBX. In December 2019 the share price was languishing at 6 GBX. So what is so different now that means SNG001, which has been around for over a decade, is going to work with CoVid-19 when the WHO in mid 2016 seem to say nothing of clinical benefit has materialised in interferon treatments in relation to previous versions of CoV? Does this thinking have any connection to SNG001 not being in the current WHO preferred clinical trial set? Here is the WHO reference along with some prophetic quotes from the same article. They were not kidding about the contents of the last paragraph quoted! In July 2016 WHO published a paper on MERS-CoV which included ... it has become clear that more strategic investments are needed in the early development of diagnostics, therapeutics and preventives against pathogens of pandemic potential. and ... As in the SARS-CoV epidemic, however, the use of treatments such as ribavirin, interferons (sic) and corticosteroids have yielded little to no clinical benefit, despite showing efficacy in nonhuman primates (NHPs) and ... In the realm of emerging infectious diseases with suspected or known pandemic potential, governmental agencies and nongovernmental organizations might have a key role in the development of interventions against diseases that do not provide a strong incentive for private-sector investments, but that are still relevant to public health and global security. and ... Although global coordination has resulted in the maturation of the preclinical pipeline for novel interventions for MERS-CoV, products will have to be developed along faster than normal timelines, with greater investments by multiple agencies for development, manufacturing and preclinical and clinical testing, as well as preparations for timely efficacy testing in affected populations if the incidence of disease rises sharply. hTtps://
rosejs2: I suspect that what we have seen Volume wise has been the sale of 2.72% of SNG sharesowned by Omnis Income & Growth fund manager. These shares were previously managed by Woodford and then removed from his management on the 9th July 2019.. I have no evidence to prove this but it makes sense (to me at least) that these shares were then transferred to a 3rd party fund manager who not fully understanding the value of these shares and not being a sufficient number / value to add to their portfolio have disposed of this holding.. The total number of shares in question would be approx. 3 million SNG shares... My further thoughts are that Woodfords 19% is still retained by LINK Investments and its associates as a block waiting for the results of either the current Phase 2 A trial results and the associate significant value increase in the share price or for a bidder such as AZT to show its hand and make a realistic bid for the block.. I do not believe that the 19% Link Holding will be sold piece meal .. what would be the point there is simply too many shares for the market to absorb and the SNG price would be further decimated...No TR1 has been issues by Link regarding the selling down of any of their 19% holding.. They are normally on the ball with TR1's as we have seen previously .. So I believe the entire 19% remains whole. If my theory is near right.. then the overhang of the Omnis share holding is virtually over .. sold primarily over the last week with significant blocks being sold down over the last few months.They have no need to issue any TR1 as their holding was below 3% The SNG share price which is completely undervalued should now start to recover substantially towards the 16-20p mark and onwards thereafter... Let us not forget that LOXL2 is thrown in for nothing and the potential royalties of any partnership arrangement for SNG could be very substantial.
rosejs2: From memory The majority of Woodfords SNG holding is in his Equity Income Fund (even though SNG has never paid any Dividend).. If there is a positive from the Woodford demise .. I suspect a number of organisations including both financial / Pharma / others will be assessing the likelihood of success of Interferon B and the value of SNG's stake in LOXL2 … The 20% plus of Woodfords holding in SNG cannot (in my opinion) just be sold through the market .. small sales tend to crash the SNG share price .. The significant stake will I believe find a new home where the value of the current portfolio can be appreciated, nurtured and monetised.. e.g. AZT or similar or an Investment Trust that focus's on Bio/Pharma investments. The elimination of the Woodford SNG overhang on the shares should see the real value of SNG shares emerge..
timbo003: Synairgen (SNG) 2019 AGM report The Synairgen 2019 AGM was held on Monday 3rd June at the offices of Fladgate LLP, 16 Great Queen Street, London. For anyone who is unfamiliar with the company, Synairgen is an AIM listed UK based biotech company focused primarily on developing new treatments for Asthma, COPD and other respiratory diseases. The company floated on AIM in November 2004, issuing approximately 8m shares at 130p/share valuing the company at around £28m. There have been several placings since the IPO; the most recent was in Sept 2018 to raise £2.9 million through the issue of around 18M ordinary Shares at a price of 16p/share (a discount of around 11%). The shares currently trade at around 13p/share valuing Synairgen at about £14m. The company broker Finncap currently have a price target of 54p/share based on a sum-of-the parts DCF, comprising c.39p/share for SNG001 and 15p/share for Pharmaxis’s LOXL2 inhibitors, in which Synairgen has a 17% economic interest Synairgen has two main assets in clinical development, the principle asset is SNG001 (inhaled beta-interferon) which is currently undergoing evaluation in a Phase II study to treat exacerbations associated with respiratory virus infections in patients with COPD. SNG001 has previously been studied in two separate Phase II studies to treat exacerbations in asthma patients with mixed success. Post hoc analysis of the results lead to the conclusion that in order for SNG001 to be effective, the exacerbation should be associated with a respiratory virus infection, therefore the presence of a viral respiratory infection is a stipulated requirement for patient entry into the current COPD study. Synairgen’s second asset is a shared interest in a Lysyl Oxidase Like homologue 2 (LOX2) program with Pharmaxis, a pharma company quoted on the Australian stock exchange (ASX: PXS) with a market cap of around £60m. LOXL2 inhibitors have shown the ability to prevent fibrosis in animal models and they should find utility in treating a range of fibrotic and pre-fibrotic diseases such as Idiopathic Pulmonary Fibrosis (IPF) and Fatty liver disease, otherwise known as Non-alcoholic steatohepatitis (NASH). There are currently 2 lead compounds from the LOXL2 program (PXS-5382 and PXS-5338) which are Phase II ready, with Pharmaxis currently conducting commercial partnering discussions with numerous large pharma companies. According to the latest available Pharmaxis investor slide deck (April 2019) and a recent Proactiveinvestor interview with the CEO (May 2019) the company hope to concluded partnering discussions during H1 2019 or Middle of the year. Synairgen are due to receive 17% of any up-front and milestone payments and 17% of any royalties received by Pharmaxis, furthermore there is no requirement for Synairgen to pay any further costs towards the development of the LOXL2 compounds. Links to last year’s AGM report, the Synairgen Web site, Annual Report and other useful information are given below: 2018 AGM report: Web site: 2019 Annual Report: Latest presentation slide deck (Feb 2019): Finncap broker notes: Formal Business There were around 15 attendees at this year’s meeting, including the BOD and representatives from the Registrar, Company Solicitor, PR representatives and the Company Broker. I was the only private shareholder present. The Chairman (Simon Shaw) told the meeting that all the directors were up for re-election this year as they had all served on the BOD for 9 years or more. I asked whether there had been any pressure to do this from large shareholders, or from ISS (Institutional Shareholder Services) who advise institutions how to vote on corporate governance resolutions. I was told that there were no such requests. All the resolutions were passed unanimously on a show of hands and the proxy votes showed large majorities in favour of all the resolutions. Q&As then followed which went on for around 30 minutes. Q&As (Note: these Q&As are paraphrased, they are not a verbatim account) LOXL2 program Q: On the LOXL2 program, what happens if Pharmaxis decide to go it alone with one or both of the LOXL2 compounds rather than out-licence to a Big Pharma partner? A: Synairgen will still get 17% of all revenue. They would forgo certain milestone payments, but longer term revenue from sales would be higher as a result. Q: Do the BOD have any preference regarding whether Pharmaxis partner now, at a later stage, or go it alone? (I had to ask this several different ways to get any sort of an answer) A: Our preference is for Pharmaxis to take whatever route gives the best long term outcome for Synaigen shareholders. Q: If Pharmaxis were to delay partnering to a later stage, or to go it alone, surely this would have an impact on the timing and quantum of Synairgen’s next funding round, so with the current lowly share price wouldn’t be in Synairgen shareholders best interest for Pharmaxis to partner early, so triggering an upfront payment to Synairgen? A: The BOD are currently focused on the COPD trial and events where they have can have some control and in particular the recruitment rate for the ongoing COPD study with SNG001. Q: Pharmaxis currently have two LOXL2 compounds which are Phase II ready and deal ready. Is there any reason to believe that one of these compounds may be more suited to NASH and the other to IPF? Or have they just developed two compounds so they can do a deal with two separate pharma companies to enable a better overall deal? A: That is a question for Pharmaxis, they own the compounds. There may be information on their web site about this. We do not have a view. (My comment: they almost certainly do have a view, but not one they are prepared to air publicly) Q: Which of the two LOXL2 indications do you consider to be the largest opportunity? A: We consider them both to be substantial opportunities (i.e. peak sales of >$ 1bn/annum) Q: I have asked before about the competition for IPF and LOXL2, has anything changed recently? A: There are two recently approved (expensive) drugs for IPF which are doing well from a commercial perspective (pirfenidone and nintedanib). Both drugs slow down disease progression, but they have not been shown to improve mortality. Neither of these two drugs have any anti-fibrotic properties. For NASH there are a couple of drugs that have reached the phase IIb stage, but they are not LOXL2 inhibitors. SNG001 for COPD Q: You mentioned that the cold/flu season had been mild this season, how mild is it and are you considering expanding the study to the southern hemisphere if recruitment rate is too slow here? A: It is less severe this season than last season and it got off to a slow start, the SNG001 study is being run in the UK, there are no plans to expand the study abroad. Q: Are infection rates picking up or do you expect them to pick up? A: There are regular reports available on cold/flu infection rates from Public Health England, we will send you the link: The recent introduction of the Biofire Filmarray has been of paramount importance for recruitment, so only patients with confirmed viral infections are recruited into the study. Not only does it confirm the presence of pathogens, it will also distinguish between bacteria and virus infections and between different viruses. Q: Should investors feel at all concerned about Faron’s unfortunate finding that steroids adversely affect the efficacy of beta interferon (Traumakine) in ARDs patients, given that many COPD patients are also likely to be on steroids? A: Absolutely not, it is a completely different mechanism Q: Would you expect beta interferon administered SC (betaferon) or IV (traumakine) to be effective in COPD patients with respiratory disease? A: No, there wouldn’t be enough drug getting to the lungs which is where the main battle against the virus takes place. Furthermore, the drug has quite a low therapeutic window, so increasing the dose significantly would not be an option. Pipeline: Q: What else are you looking at regarding the future Pipeline? A: One big opportunity would be to extend the use of SNG beyond COPD patients (or asthmatics). Some groups of patients are particularly vulnerable to respiratory tract viral infections, for example diabetics and patients with some CNS disorders (for example stroke). There are many diabetics who present at A&E with difficulty breathing as a result of a respiratory tract viral infection and there is currently not much you can do for them. The only drug treatments available are Tamiflu and Relenza, but neither is particularly effective. Q: Is there a reason to believe that you could use the LOXL2 inhibitors for cystic fibrosis, given that LOXL2 inhibitors are anti-fibrotic? A: No, cystic fibrosis is a bit of a misnomer as there is no fibrosis present in CF. Q: Is there a reason to believe that you could use SNG001 for respiratory viral infections for cystic fibrosis? A: Yes Recommended reading: Tamiflu and Relenza review questions effectiveness against flu (2014) Infections in patients with diabetes mellitus: A review of pathogenesis (2012) Increased Risk of Common Infections in Patients with Type 1 and Type 2 Diabetes Mellitus (2005)
ohisay: I was just checking back to see the implied market cap of the SNG share price when AZN farmed into SNG001 in 2014. On the morning of the deal the share price ran up to 70p/75p but there were 78m shares in issue then; so adjusting for the current 110m would equate to 50p+ per share. SNG were a one trick pony at the time - they didnt have the LOXL2 upside then - so throughout the AZN asthma trial the price slipped back to under 40p. If the current ability to do cheap trials on COPD had been available to AZN after the inconclusive asthma results (through the novel point of care diagnostic tool) I doubt they would have handed back SNG001 to SNG. So if the SNG COPD phase 2 trial here is successful in Q2 its not beyond the bounds of possibility AZN could be back to finance a phase 2B .Marsden has said as much and with a trial size of 190 patients up from the original 120 it isnt as if they wont have substantive data in front of them. The numbers Finncap are ultimately talking about in that case are not wildly different to that 2014 deal; COPD is still a largely unmet clinical need after all. Idle musings perhaps... [More interim news next month.03/15/19 2018 Earnings Release (Projected)]
Synairgen share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200527 22:50:48